These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31572244)

  • 1. Human Autoantibodies Against N-Methyl-D-Aspartate Receptor Modestly Alter Dopamine D1 Receptor Surface Dynamics.
    Gréa H; Bouchet D; Rogemond V; Hamdani N; Le Guen E; Tamouza R; Darrau E; Passerieux C; Honnorat J; Leboyer M; Groc L
    Front Psychiatry; 2019; 10():670. PubMed ID: 31572244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMDAR Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice.
    Carceles-Cordon M; Mannara F; Aguilar E; Castellanos A; Planagumà J; Dalmau J
    Ann Neurol; 2020 Sep; 88(3):603-613. PubMed ID: 32583480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study.
    Kelleher E; McNamara P; Dunne J; Fitzmaurice B; Heron EA; Whitty P; Walsh R; Mooney C; Hogan D; Conlon N; Gill M; Vincent A; Doherty CP; Corvin A
    Schizophr Res; 2020 Aug; 222():455-461. PubMed ID: 32499165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Fiorentini C; Rizzetti MC; Busi C; Bontempi S; Collo G; Spano P; Missale C
    Mol Pharmacol; 2006 Mar; 69(3):805-12. PubMed ID: 16365282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients.
    Jézéquel J; Johansson EM; Dupuis JP; Rogemond V; Gréa H; Kellermayer B; Hamdani N; Le Guen E; Rabu C; Lepleux M; Spatola M; Mathias E; Bouchet D; Ramsey AJ; Yolken RH; Tamouza R; Dalmau J; Honnorat J; Leboyer M; Groc L
    Nat Commun; 2017 Nov; 8(1):1791. PubMed ID: 29176681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenicity of Antibodies against NMDA Receptor: Molecular Insights into Autoimmune Psychosis.
    Jézéquel J; Johansson EM; Leboyer M; Groc L
    Trends Neurosci; 2018 Aug; 41(8):502-511. PubMed ID: 29807730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies against N-methyl-d-aspartate receptor 1 in health and disease.
    Ehrenreich H
    Curr Opin Neurol; 2018 Jun; 31(3):306-312. PubMed ID: 29474316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell- and Single Molecule-Based Methods to Detect Anti-N-Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project.
    Jézéquel J; Rogemond V; Pollak T; Lepleux M; Jacobson L; Gréa H; Iyegbe C; Kahn R; McGuire P; Vincent A; Honnorat J; Leboyer M; Groc L
    Biol Psychiatry; 2017 Nov; 82(10):766-772. PubMed ID: 28780967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-nMDA receptor encephalitis--clinical manifestations and pathophysiology].
    Iizuka T; Sakai F
    Brain Nerve; 2008 Sep; 60(9):1047-60. PubMed ID: 18807939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Layer-specific effects of dopaminergic D1 receptor activation on excitatory synaptic trains in layer V mouse prefrontal cortical pyramidal cells.
    Leyrer-Jackson JM; Thomas MP
    Physiol Rep; 2018 Aug; 6(15):e13806. PubMed ID: 30073790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.
    Hammer C; Stepniak B; Schneider A; Papiol S; Tantra M; Begemann M; Sirén AL; Pardo LA; Sperling S; Mohd Jofrry S; Gurvich A; Jensen N; Ostmeier K; Lühder F; Probst C; Martens H; Gillis M; Saher G; Assogna F; Spalletta G; Stöcker W; Schulz TF; Nave KA; Ehrenreich H
    Mol Psychiatry; 2014 Oct; 19(10):1143-9. PubMed ID: 23999527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor.
    Hara M; Martinez-Hernandez E; Ariño H; Armangué T; Spatola M; Petit-Pedrol M; Saiz A; Rosenfeld MR; Graus F; Dalmau J
    Neurology; 2018 Apr; 90(16):e1386-e1394. PubMed ID: 29549218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis.
    Mikasova L; De Rossi P; Bouchet D; Georges F; Rogemond V; Didelot A; Meissirel C; Honnorat J; Groc L
    Brain; 2012 May; 135(Pt 5):1606-21. PubMed ID: 22544902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tracking single membrane targets of human autoantibodies using single nanoparticle imaging.
    Jézéquel J; Dupuis JP; Maingret F; Groc L
    J Neurosci Methods; 2018 Jul; 304():76-82. PubMed ID: 29684464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4.
    Ogundele OM; Lee CC
    Brain Res Bull; 2018 Mar; 137():53-70. PubMed ID: 29137928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of NMDA receptor trafficking as a cellular hallmark of psychosis.
    Espana A; Seth H; Jézéquel J; Huang T; Bouchet D; Lepleux M; Gréa H; Bechter K; Schneider M; Hanse E; Groc L
    Transl Psychiatry; 2021 Aug; 11(1):444. PubMed ID: 34462417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis.
    Pollak TA; Kempton MJ; Iyegbe C; Vincent A; Irani SR; Coutinho E; Menassa DA; Jacobson L; de Haan L; Ruhrmann S; Sachs G; Riecher-Rössler A; Krebs MO; Amminger P; Glenthøj B; Barrantes-Vidal N; van Os J; Rutten BPF; Bressan RA; van der Gaag M; Yolken R; Hotopf M; Valmaggia L; Stone J; David AS; ; McGuire P
    Mol Psychiatry; 2021 Jun; 26(6):2590-2604. PubMed ID: 33077853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmunity and NMDA receptor in brain disorders: Where do we stand?
    Hunter D; Jamet Z; Groc L
    Neurobiol Dis; 2021 Jan; 147():105161. PubMed ID: 33166697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.
    Warikoo N; Brunwasser SJ; Benz A; Shu HJ; Paul SM; Lewis M; Doherty J; Quirk M; Piccio L; Zorumski CF; Day GS; Mennerick S
    J Neurosci; 2018 Mar; 38(13):3218-3229. PubMed ID: 29476014
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoantibodies against NMDA receptor 1 modify rather than cause encephalitis.
    Wilke JBH; Hindermann M; Berghoff SA; Zihsler S; Arinrad S; Ronnenberg A; Barnkothe N; Steixner-Kumar AA; Röglin S; Stöcker W; Hollmann M; Nave KA; Lühder F; Ehrenreich H
    Mol Psychiatry; 2021 Dec; 26(12):7746-7759. PubMed ID: 34331009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.